Semaglutide + AOD-9604 — claim review
A licensed UK medicine paired with an unlicensed compound. This page is a claim-vs-evidence analysis of the combination — how it is marketed, what the evidence supports, and the regulatory asymmetry consumers should understand.
What people claim about this stack
- “Greater fat loss than semaglutide alone”
- “Preserves muscle while losing fat”
- “Speeds up weight loss in plateaus”
- “Safer than higher-dose semaglutide”
- “Clinically used for years overseas”
Why this stack is popular at clinics
Demand for GLP-1 weight loss has been intense. Adding a second compound is commercially attractive — it lets a clinic differentiate its “programme” and charge more, while the underlying GLP-1 is doing most of the clinical work. That is not, by itself, a reason to combine.
Evidence for each individual compound
- Semaglutide: robust human RCT base. Licensed UK medicine (Ozempic for type 2 diabetes; Wegovy for chronic weight management). Evidence grade A.
- AOD-9604: a modified fragment of growth hormone studied for fat metabolism. Earlier development for obesity did not produce a licensed product; human evidence for normal adults is limited. Evidence grade roughly C–D, with regulatory risk.
Evidence for the combination
There are essentially no robust human RCTs of the combination. The marketing claim of “more fat loss than semaglutide alone” is mechanistic speculation combined with anecdote. Whether AOD-9604 adds meaningful clinical benefit on top of GLP-1 in eligible patients is not established.
UK regulatory considerations
- Semaglutide is a UK POM — lawful supply requires a UK prescriber and a regulated pharmacy.
- AOD-9604 has no UK marketing authorisation. Clinics offering it for weight loss face the same regulatory questions as for other unlicensed peptides.
- The regulatory protections (PIL, MAH details, Yellow Card, pharmacy accountability) apply only to the licensed component.
Safety uncertainties
- Combining a regulated medicine with an unregulated compound makes side-effect attribution harder.
- Identity, purity, and dose accuracy of grey-market AOD-9604 are unverified.
- Long-term outcomes of the combination are not well-characterised.
- Stopping the regulated medicine because of an adverse event from the unregulated one becomes a more complicated clinical decision.
Sport / doping concerns
AOD-9604 is generally treated as prohibited under WADA's S0 non-approved substances category. GLP-1 receptor agonist status under WADA can change — confirm with current WADA / UKAD guidance. Strict liability applies.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“More effective than Wegovy alone”
No robust head-to-head human data support the combination claim.
“Speeds you through a plateau”
Plateau management is best handled by reviewing the underlying programme and the prescriber's plan, not by adding an unlicensed compound.
“Spares muscle during weight loss”
AOD-9604's effect on lean mass in adults is not robustly established. Resistance training has stronger evidence.
“Used in our private programme — fully legal”
Combining a POM and an unlicensed compound is not 'fully legal' as a single regulated treatment.
Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Greater fat loss than semaglutide alone” | E | No | High | No robust human RCTs of the combination exist. |
| “Preserves muscle better than semaglutide alone” | E | No | High | Muscle preservation is best supported by resistance training and adequate protein intake. |
| “AOD-9604 is licensed in the UK” | E | No | High | AOD-9604 is not a licensed UK medicine. |
| “Safer than a higher dose of semaglutide” | E | No | High | Comparative safety claims require comparative human data; none exists. |
Safer alternatives to discuss with a qualified clinician
- Reviewing dose-escalation, adherence, and lifestyle interventions within the licensed semaglutide programme.
- Considering tirzepatide where appropriate and licensed for the indication.
- Structured resistance training and dietary planning for muscle preservation.
- Realistic expectations and a documented plan for ongoing care and stopping criteria.
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is the combination of semaglutide and AOD-9604 a licensed UK option?
- What is the evidence that adding AOD-9604 changes outcomes?
- What is your protocol if I have a side effect — and which medicine is responsible?
- What is the clinic's commercial relationship with the supplier of AOD-9604?
- Are there licensed alternatives we should be discussing first?
Frequently asked questions
- Is semaglutide + AOD-9604 a licensed UK combination?
- Semaglutide is a UK prescription-only medicine. AOD-9604 is not a licensed UK medicine. There is no licensed UK combination — what is being marketed is a combination of a regulated medicine with an unregulated compound.
- Why are clinics pairing them?
- Semaglutide drives substantial weight loss in eligible patients; adding AOD-9604 is marketed as 'further enhancing fat loss'. The mechanistic story is appealing but the human-outcomes evidence for the combination is not established.
- What does the evidence support?
- Semaglutide has robust human RCT evidence for weight management in defined populations. AOD-9604 has limited human evidence for weight-related outcomes in normal adults. There are no robust human RCTs of the combination.
- Are there extra side-effect risks from combining?
- Pharmacokinetic and pharmacodynamic interactions of adding an unlicensed compound to a regulated medicine are not well characterised. Side-effect attribution becomes harder. Any adverse event response is more complex.
- Is this combination prohibited in sport?
- AOD-9604 is generally treated as prohibited under WADA's S0 category. GLP-1 status should be confirmed with current WADA / UKAD guidance.